Skip to content
The Kids Research Institute Australia logo
Donate

Discover . Prevent . Cure .

Professor Tobias Kollmann

Honorary Research Associate

Tobias Kollmann

Honorary Research Associate

PhD, M.D., SFUW

tobias.kollmann@telethonkids.org.au

+61 8 6319 1050

Professor Tobias Kollmann is a paediatric infectious diseases physician with a deep passion for making an impact at the convergence of clinical care and fundamental research. He is an Honorary Research Associate with the Immunology and Breast Feeding team at The Kids Research Institute Australia.

Professor Kollmann completed both his MD and PhD at the Albert Einstein College of Medicine, New York, USA. He then conducted his Residency and Fellowship at the University of Washington, Seattle, USA, before joining the Paediatric Infectious Disease Division at the University of British Columbia (UBC), Canada in 2005. 

As a member of the WHO Expert Advisory Group on Non-specific Immunological Effects of Vaccination committee, Professor Kollmann is international leader in vaccinology. He is a member on multiple NIH Review panels associated with the National Institute of Allergy and Infectious Disease (NIAID) including Human Immunology Project Consortium, Centres of Excellence in Translational Research and Cooperative Centres on Human Immunology.

Projects

Containing Coronavirus Disease 19 (ConCorD-19)

FluBubs: Safety and immunogenicity of Early Quadrivalent Influenza Vaccine

Working Towards a Better Understanding of ARF

Towards a diagnostic test for rheumatic fever

Published research

BCG vaccination of healthcare workers for protection against COVID-19: 12-month outcomes from an international randomised controlled trial

Bacille Calmette-Guérin (BCG) vaccine has immunomodulatory effects that may provide protection against unrelated infectious diseases. We aimed to determine whether BCG vaccination protects adults against COVID-19. 

The mark of success: The role of vaccine-induced skin scar formation for BCG and smallpox vaccine-associated clinical benefits

Skin scar formation following Bacille Calmette-Guérin (BCG) or smallpox (Vaccinia) vaccination is an established marker of successful vaccination and 'vaccine take'. Potent pathogen-specific (tuberculosis; smallpox) and pathogen-agnostic (protection from diseases unrelated to the intentionally targeted pathogen) effects of BCG and smallpox vaccines hold significant translational potential.

Breastfeeding and Neonatal Age Influence Neutrophil-Driven Ontogeny of Blood Cell Populations in the First Week of Human Life

The first few days of life are characterized by rapid external and internal changes that require substantial immune system adaptations. Despite growing evidence of the impact of this period on lifelong immune health, this period remains largely uncharted. 

Molecular analysis of human tick-bitten skin yields signatures associated with distinct spatial and temporal trajectories - A proof-of-concept study

Tick-associated diseases present challenges due to tridirectional interactions among host-specific responses, tick toxins and salivary proteins as well as microbes. We aimed to uncover molecular mechanisms in tick-bitten skin samples and contralateral skin samples collected simultaneously from the same participants, using spatial transcriptomics.

Angiogenesis-associated pathways play critical roles in neonatal sepsis outcomes

Neonatal sepsis is a major cause of childhood mortality. Limited diagnostic tools and mechanistic insights have hampered our abilities to develop prophylactic or therapeutic interventions. Biomarkers in human neonatal sepsis have been repeatedly identified as associated with dysregulation of angiopoietin signaling and altered arachidonic acid metabolism. 

Randomized Trial of BCG Vaccine to Protect against Covid-19 in Health Care Workers

The bacille Calmette-Guérin (BCG) vaccine has immunomodulatory "off-target" effects that have been hypothesized to protect against coronavirus disease 2019. 

Interferon β-1a ring prophylaxis to reduce household transmission of SARS-CoV-2: a cluster randomised clinical trial

Accumulating evidence indicates that an early, robust type 1 interferon (IFN) response to SARS-CoV-2 is important in determining COVID-19 outcomes, with an inadequate IFN response associated with disease severity. Our objective was to examine the prophylactic potential of IFN administration to limit viral transmission.

BCG-Induced Immune Training: Interplay between Trained Immunity and Emergency Granulopoiesis

Bacille Calmette-Guérin (BCG) is the most commonly administered vaccine in human history. The medical application of BCG extends far beyond the fight against tuberculosis. Despite its stellar medical record over 100 years, insight into how BCG provides this vast range of benefits is largely limited, both for its pathogen-specific (tuberculosis) as well as pathogen-agnostic (other infections, autoimmunity, allergies, and cancer) effects.

Defining the pediatric response to SARS-CoV-2 variants

The global population has been severely affected by the coronavirus disease 2019 (COVID-19) pandemic, however, with older age identified as a risk factor, children have been underprioritized. This article discusses the factors contributing to the less severe response observed in children following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), including, differing viral entry receptor expression and immune responses.

Maternal Vaccination to Prevent Adverse Pregnancy Outcomes: An Underutilized Molecular Immunological Intervention?

Adverse pregnancy outcomes including maternal mortality, stillbirth, preterm birth, intrauterine growth restriction cause millions of deaths each year. More effective interventions are urgently needed. Maternal immunization could be one such intervention protecting the mother and newborn from infection through its pathogen-specific effects.

The non-specific effects of maternal immunization on birth outcomes: The evidence, mechanisms, and the implications

Preterm birth (PTB) and stillbirth remain two of the most important causes of death, morbidity, and disability in childhood. Despite efforts to reduce PTB and stillbirth worldwide, rates of these adverse outcomes remain persistently elevated, independent of income setting. There is an urgent need for more effective interventions to reduce associated neonatal and early childhood morbidity and mortality.

Implications of Non-Specific Effects for Testing, Approving, and Regulating Vaccines

The current framework for testing and regulating vaccines was established before the realization that vaccines, in addition to their effect against the vaccine-specific disease, may also have "non-specific effects" affecting the risk of unrelated diseases. Accumulating evidence from epidemiological studies shows that vaccines in some situations can affect all-cause mortality and morbidity in ways that are not explained by the prevention of the vaccine-targeted disease.

The Troublesome Ticks Research Protocol: Developing a Comprehensive, Multidiscipline Research Plan for Investigating Human Tick-Associated Disease in Australia

In Australia, there is a paucity of data about the extent and impact of zoonotic tick-related illnesses. Even less is understood about a multifaceted illness referred to as Debilitating Symptom Complexes Attributed to Ticks (DSCATT). Here, we describe a research plan for investigating the aetiology, pathophysiology, and clinical outcomes of human tick-associated disease in Australia.

Off-target effects of bacillus Calmette-Guerin vaccination on immune responses to SARS-CoV-2: implications for protection against severe COVID-19

Because of its beneficial off-target effects against non-mycobacterial infectious diseases, bacillus Calmette-Guérin vaccination might be an accessible early intervention to boost protection against novel pathogens. Multiple epidemiological studies and randomised controlled trials are investigating the protective effect of BCG against coronavirus disease 2019 (COVID-19).

A systems biology approach to better understand human tick-borne diseases

Tick-borne diseases are a growing global health concern. Despite extensive studies, ill-defined tick-associated pathologies remain with unknown aetiologies. Human immunological responses after tick bite, and inter-individual variations of immune-response phenotypes, are not well characterised.

FastMix: a versatile data integration pipeline for cell type-specific biomarker inference

Flow cytometry (FCM) and transcription profiling are the two widely used assays in translational immunology research. However, there is no data integration pipeline for analyzing these two types of assays together with experiment variables for biomarker inference.

Ancestral SARS-CoV-2, but not Omicron, replicates less efficiently in primary pediatric nasal epithelial cells

Children typically experience more mild symptoms of Coronavirus Disease 2019 (COVID-19) when compared to adults. There is a strong body of evidence that children are also less susceptible to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection with the ancestral viral isolate.

The safety of co-administration of Bacille Calmette-Guérin (BCG) and influenza vaccines

With the emergence of novel vaccines and new applications for older vaccines, co-administration is increasingly likely. The immunomodulatory effects of BCG could theoretically alter the reactogenicity of co-administered vaccines. Using active surveillance in a randomised controlled trial, we aimed to determine whether co-administration of BCG vaccination changes the safety profile of influenza vaccination.

Bacille Calmette-Guérin vaccine reprograms human neonatal lipid metabolism in vivo and in vitro

Vaccines have generally been developed with limited insight into their molecular impact. While systems vaccinology enables characterization of mechanisms of action, these tools have yet to be applied to infants, who are at high risk of infection and receive the most vaccines. Bacille Calmette-Guérin (BCG) protects infants against disseminated tuberculosis (TB) and TB-unrelated infections via incompletely understood mechanisms.

Cutaneous CpG adjuvant conditioning to enhance vaccine responses

Adjuvant activity of the Toll receptor 9 agonist CpG 1826 was compared when given subcutaneously (s.c.) together with ovalbumin (s.c.[CpG + Ova]), or when given by either s.c. or intradermally (i.d.) routes two days prior to s.c. ovalbumin.

Revaccination with Bacille Calmette-Guérin (BCG) is associated with an increased risk of abscess and lymphadenopathy

The reported frequency and types of adverse events following initial vaccination and revaccination with Bacille Calmette-Guérin (BCG) varies worldwide. Using active surveillance in a randomised controlled trial of BCG vaccination (the BRACE trial), we determined the incidence and risk factors for the development of BCG injection site abscess and regional lymphadenopathy.

Machine Learning-Based Single Cell and Integrative Analysis Reveals That Baseline mDC Predisposition Correlates With Hepatitis B Vaccine Antibody Response

Vaccination to prevent infectious disease is one of the most successful public health interventions ever developed. And yet, variability in individual vaccine effectiveness suggests that a better mechanistic understanding of vaccine-induced immune responses could improve vaccine design and efficacy.

BCG vaccination to reduce the impact of COVID-19 in healthcare workers: Protocol for a randomised controlled trial (BRACE trial)

BCG vaccination modulates immune responses to unrelated pathogens. This off-target effect could reduce the impact of emerging pathogens. As a readily available, inexpensive intervention that has a well-established safety profile, BCG is a good candidate for protecting healthcare workers (HCWs) and other vulnerable groups against COVID-19.

Lactiplantibacillus plantarum–Nomad and Ideal Probiotic

Probiotics are increasingly recognized as capable of positively modulating several aspects of human health. There are numerous attributes that make an ideal probiotic. Lactiplantibacillus plantarum (Lp) exhibits an ecological and metabolic flexibility that allows it to thrive in a variety of environments.

Ontogeny of plasma cytokine and chemokine concentrations across the first week of human life

Early life is marked by distinct and rapidly evolving immunity and increased susceptibility to infection. The vulnerability of the newborn reflects development of a complex immune system in the face of rapidly changing demands during the transition to extra-uterine life.

Searching for a technology-driven acute rheumatic fever test: the START study protocol

The absence of a diagnostic test for acute rheumatic fever (ARF) is a major impediment in managing this serious childhood condition. ARF is an autoimmune condition triggered by infection with group A Streptococcus.

A cluster randomized trial of interferon ss-1a for the reduction of transmission of SARS-Cov-2: protocol for the Containing Coronavirus Disease 19 trial (ConCorD-19)

SARS-CoV-2 infection rapidly spreads in populations due to the high rates of community transmission. Interrupting the shedding of SARS-CoV-2 may reduce the incidence of Coronavirus Disease 19 (COVID-19).

Bacterial and Fungal Gut Community Dynamics Over the First 5 Years of Life in Predominantly Rural Communities in Ghana

Bacterial and fungal microbiotas are increasingly recognized as important in health and disease starting early in life. However, microbiota composition has not yet been investigated in most rural, low-resource settings, and in such settings, bacterial and fungal microbiotas have not been compared.

Immunological mechanisms of vaccine-induced protection against COVID-19 in humans

Most COVID-19 vaccines are designed to elicit immune responses, ideally neutralizing antibodies (NAbs), against the SARS-CoV-2 spike protein. Several vaccines, including mRNA, adenoviral-vectored, protein subunit and whole-cell inactivated virus vaccines, have now reported efficacy in phase III trials and have received emergency approval in many countries.

Plasma Adenosine Deaminase (ADA)-1 and -2 Demonstrate Robust Ontogeny Across the First Four Months of Human Life

Human adenosine deaminases (ADAs) modulate the immune response: ADA1 via metabolizing adenosine, a purine metabolite that inhibits pro-inflammatory and Th1 cytokine production, and the multi-functional ADA2, by enhancing T-cell proliferation and monocyte differentiation. Newborns are relatively deficient in ADA1 resulting in elevated plasma adenosine concentrations and a Th2/anti-inflammatory bias compared to adults.

Immunisation with the BCG and DTPw vaccines induces different programs of trained immunity in mice

In addition to providing pathogen-specific immunity, vaccines can also confer nonspecific effects (NSEs) on mortality and morbidity unrelated to the targeted disease. Immunisation with live vaccines, such as the BCG vaccine, has generally been associated with significantly reduced all-cause infant mortality. In contrast, some inactivated vaccines, such as the diphtheria, tetanus, whole-cell pertussis (DTPw) vaccine, have been controversially associated with increased all-cause mortality especially in female infants in high-mortality settings.

A place for neutrophils in the beneficial pathogen-agnostic effects of the BCG vaccine

The BCG vaccine has long been recognized for reducing the risk to suffer from infectious diseases unrelated to its target disease, tuberculosis. Evidence from human trials demonstrate substantial reductions in all-cause mortality, especially in the first week of life. Observational studies have identified an association between BCG vaccination and reduced risk of respiratory infectious disease and clinical malaria later in childhood.

One vaccine for life: Lessons from immune ontogeny

There remains a general misconception that the immune status of the fetus and neonate is immature or insufficient. However, emerging research in immune ontogeny prompts reconsideration of this orthodoxy, reframing this period instead as one of unique opportunity. Vaccine responses (qualitative and quantitative) vary between individuals, and across demographic cohorts. Elements of baseline immune status and function predict vaccine response - some of these factors are well described, others remain a subject of ongoing research, especially with the rapidly expanding field of 'omics' research, enabled by development of highly granular immune profiling techniques and increasing computational capacity.

The Fifth International Neonatal and Maternal Immunization Symposium (INMIS 2019): Securing Protection for the Next Generation

Despite significant progress in reaching some milestones of the United Nations Sustainable Development Goals, neonatal and early infant morbidity and mortality remain high, and maternal health remains suboptimal in many countries. Novel and improved preventative strategies with the potential to benefit pregnant women and their infants are needed, with maternal and neonatal immunization representing effective approaches.

Biogeography of the Relationship between the Child Gut Microbiome and Innate Immune System

The gut microbiome is a well-recognized modulator of host immunity, and its compositions differ between geographically separated human populations. Systemic innate immune responses to microbial derivatives also differ between geographically distinct human populations. However, the potential role of the microbiome in mediating geographically varied immune responses is unexplored. We here applied 16S amplicon sequencing to profile the stool microbiome and, in parallel, measured whole-blood innate immune cytokine responses to several pattern recognition receptor (PRR) agonists among 2-year-old children across biogeographically diverse settings. Microbiomes differed mainly between high- and low-resource environments and were not strongly associated with other demographic factors. We found strong correlations between responses to Toll-like receptor 2 (TLR2) and relative abundances of Bacteroides and Prevotella populations, shared among Canadian and Ecuadorean children.

Multi-Omic Data Integration Allows Baseline Immune Signatures to Predict Hepatitis B Vaccine Response in a Small Cohort

Vaccination remains one of the most effective means of reducing the burden of infectious diseases globally. Improving our understanding of the molecular basis for effective vaccine response is of paramount importance if we are to ensure the success of future vaccine development efforts. We applied cutting edge multi-omics approaches to extensively characterize temporal molecular responses following vaccination with hepatitis B virus (HBV) vaccine. Data were integrated across cellular, epigenomic, transcriptomic, proteomic, and fecal microbiome profiles, and correlated to final HBV antibody titres.

Systems Biology Methods Applied to Blood and Tissue for a Comprehensive Analysis of Immune Response to Hepatitis B Vaccine in Adults

Conventional vaccine design has been based on trial-and-error approaches, which have been generally successful. However, there have been some major failures in vaccine development and we still do not have highly effective licensed vaccines for tuberculosis, HIV, respiratory syncytial virus, and other major infections of global significance. Approaches at rational vaccine design have been limited by our understanding of the immune response to vaccination at the molecular level. Tools now exist to undertake in-depth analysis using systems biology approaches, but to be fully realized, studies are required in humans with intensive blood and tissue sampling.

Innate Immune Responses and Gut Microbiomes Distinguish HIV-Exposed from HIV-Unexposed Children in a Population-Specific Manner

In both high- and low-income countries, HIV-negative children born to HIV-positive mothers (HIV exposed, uninfected [HEU]) are more susceptible to severe infection than HIV-unexposed, uninfected (HUU) children, with altered innate immunity hypothesized to be a cause. Both the gut microbiome and systemic innate immunity differ across biogeographically distinct settings, and the two are known to influence each other.

The non-specific and sex-differential effects of vaccines

The textbook view of vaccination is that it functions to induce immune memory of the specific pathogen components of the vaccine, leading to a quantitatively and qualitatively better response if the host is exposed to infection with the same pathogen

Improving Vaccine-Induced Immunity: Can Baseline Predict Outcome?

Baseline signatures might contribute to identifying interventional targets to be modulated prior to vaccination in order to improve vaccination responses

Interferon-α2b Treatment for COVID-19

We describe here the effects of treatment with interferon-α2b in a cohort of confirmed COVID-19 cases in Wuhan, China

Vaccination strategies to enhance immunity in neonates

Protection may be further improved by integrating these approaches, namely vaccinating the neonate under the cover of vertically transferred maternal immunity

BCG vaccination-induced emergency granulopoiesis provides rapid protection from neonatal sepsis

We found that BCG, in a mouse model of neonatal polymicrobial sepsis, induced granulocyte colony-stimulating factor (G-CSF) within hours of administration

Maternal HIV infection alters antimicrobial immunity in exposed and uninfected infants

Implementation of lifelong ART of all HIV-infected women has the potential to improve maternal determinants of protective immunity in the young infant

Clinical protocol for a longitudinal cohort study to identify markers of vaccine immunogenicity in newborn infants in the gambia and papua New Guinea

Immunity is distinct in early life and greater precision is required in our understanding of mechanisms of early life protection to inform development of new pediatric vaccines

Malt1 deficient mice develop osteoporosis independent of osteoclast-intrinsic effects of Malt1 deficiency

Malt1 deficient mice develop an osteoporotic phenotype with increased osteoclastogenesis in vivo, but suggest that this is caused by inflammation

Education and Qualifications

1995: PhD, Albert Einstein College of Medicine Bronx, New York, USA

1998: M.D. Albert Einstein College of Medicine Bronx, New York, USA

2001: Residency, University of Washington Seattle, Washington, USA

2004: Senior Fellowship, University of Washington Seattle, Washington, USA

Awards and Honours

1998 - Alpha Omega Alpha (AOA), National Honor Medical Society

2001–2004 - Pfizer Postdoctoral Fellowship in Infectious Diseases

2005–2010 - Burroughs Welcome Fund Career Award in the Biomedical Sciences

2007–2011 - Canadian Child Health Clinician Scientist Career Development Award

2012–2020 - Michael Smith Foundation for Health Research Career Investigator Award

External Committees

2009–2010
Member, External Advisory Board (EAB), U.S. National Institute of Allergy and Infectious Disease (NIAID), Bioinformatics Integration Support Contract (BISC) program

2010
NIH Review Panel, Recovery Act Limited Competition: Protection of Human Health by Immunology and Vaccines (U01, U19)

2011
NIH Review Panel, NIAID Human Immunology Project Consortium

2010–2012
External Reviewer, Welcome Trust, UK

2009–2013
External Reviewer, South Africa’s National Research Foundation, RSA

2013
Royal College of Physicians & Surgeons of Canada

2013
Canadian Coalition for Global Health Research

2013
NIH Review Panel (U19), NIAID Centers of Excellence in Translational Research

2014
NIH Review Panel (U19), NIAID Cooperative Centers on Human Immunology

2014
Canadian Paediatric Society

2015
World Health Organization (WHO)

Expert Advisory Group on Non-specific Immunological Effects of Vaccination

2016
Human Vaccine Project

2016
Member, CIHR College of Reviewers

Other Publications

1. Reduced genetic potential for butyrate fermentation in the gut microbiome of infants who develop allergic sensitization. Cait A, Cardenas E, Dimitriu P, Amenyogbe N, Dai D, Cait J, Sbihi H, Stiemsma L, Subbarao P, Mandhane PJ, Becker AB, Moraes TJ, Sears MR, Lefebvre DL, Azad MB, Kollmann T, Turvey SE, Mohn WW. J Allergy Clin Immunol. 2019 Jul 3. pii: S0091-6749(19)30891-7. doi: 10.1016/j.jaci.2019.06.029. [Epub ahead of print]

2. Robust health-score based survival prediction for a neonatal mouse model of polymicrobial sepsis. Brook B, Harbeson D, Amenyogbe N, Ben-Othman R, Kollmann TR, Aniba R. PLoS One. 2019 Jun 24;14(6):e0218714. doi: 10.1371/journal.pone.0218714. eCollection 2019.

3. Dynamic molecular changes during the first week of human life follow a robust developmental trajectory. Lee AH, Shannon CP, Amenyogbe N, Bennike TB, Diray-Arce J, Idoko OT, Gill EE, Ben-Othman R, Pomat WS, van Haren SD, Cao KL, Cox M, Darboe A, Falsafi R, Ferrari D, Harbeson DJ, He D, Bing C, Hinshaw SJ, Ndure J, Njie-Jobe J, Pettengill MA, Richmond PC, Ford R, Saleu G, Masiria G, Matlam JP, Kirarock W, Roberts E, Malek M, Sanchez-Schmitz G, Singh A, Angelidou A, Smolen KK; EPIC Consortium, Brinkman RR, Ozonoff A, Hancock REW, van den Biggelaar AHJ, Steen H, Tebbutt SJ, Kampmann B, Levy O, Kollmann TR.
Nat Commun. 2019 Mar 12;10(1):1092. doi: 10.1038/s41467-019-08794-x.

4. A Controlled Mouse Model for Neonatal Polymicrobial Sepsis. Brook B, Amenyogbe N, Ben-Othman R, Cai B, Harbeson D, Francis F, Liu AC, Varankovich N, Wynn J, Kollmann TR. J Vis Exp. 2019 Jan 27;(143). doi: 10.3791/58574.

5. Probiotic Studies in Neonatal Mice Using Gavage. Francis F, Varankovich N, Brook B, Amenyogbe N, Ben-Othman R, Cai B, Harbeson D, Liu AC, Dai B, McErlane S, Andrews K, Kollmann TR, Panigrahi P. J Vis Exp. 2019 Jan 27;(143). doi: 10.3791/59074.

6. Initiation of Antiretroviral Therapy Before Pregnancy Reduces the Risk of Infection-related Hospitalization in Human Immunodeficiency Virus-exposed Uninfected Infants Born in a High-income Country. Goetghebuer T, Smolen KK, Adler C, Das J, McBride T, Smits G, Lecomte S, Haelterman E, Barlow P, Piedra PA, van der Klis F, Kollmann TR, Lauffenburger DA, Alter G, Levy J, Marchant A. Clin Infect Dis. 2019 Mar 19;68(7):1193-1203. doi: 10.1093/cid/ciy673.

7. Energy Demands of Early Life Drive a Disease Tolerant Phenotype and Dictate Outcome in Neonatal Bacterial Sepsis. Harbeson D, Francis F, Bao W, Amenyogbe NA, Kollmann TR. Front Immunol. 2018 Aug 23;9:1918. doi: 10.3389/fimmu.2018.01918. eCollection 2018.

8. Outgrowing the Immaturity Myth: The Cost of Defending From Neonatal Infectious Disease. Harbeson D, Ben-Othman R, Amenyogbe N, Kollmann TR. Front Immunol. 2018 May 29;9:1077. doi: 10.3389/fimmu.2018.01077. eCollection 2018.

9. Innate immune responses following Kawasaki disease and toxic shock syndrome. Chen KYH, Messina N, Germano S, Bonnici R, Freyne B, Cheung M, Goldsmith G, Kollmann TR, Levin M, Burgner D, Curtis N. PLoS One. 2018 Feb 15;13(2):e0191830. doi: 10.1371/journal.pone.0191830. eCollection 2018.

10. Adjuvant Effect of Bacille Calmette-Guérin on Hepatitis B Vaccine Immunogenicity in the Preterm and Term Newborn. Scheid A, Borriello F, Pietrasanta C, Christou H, Diray-Arce J, Pettengill MA, Joshi S, Li N, Bergelson I, Kollmann T, Dowling DJ, Levy O. Front Immunol. 2018 Jan 24;9:29. doi: 10.3389/fimmu.2018.00029. eCollection 2018.

11. Neonatal BCG Vaccination Influences Cytokine Responses to Toll-like Receptor Ligands and Heterologous Antigens. Freyne B, Donath S, Germano S, Gardiner K, Casalaz D, Robins-Browne RM, Amenyogbe N, Messina NL, Netea MG, Flanagan KL, Kollmann T, Curtis N.

12. The Western environment reduces innate immune cytokine production in Chinese immigrants. Saiganesh A, Hales BJ, Chen S, Filipovska-Naumovska E, Pereira G, Garand M, Kollmann TR, Currie AJ, Le Souëf PN, Zhang G. J Allergy Clin Immunol. 2018 Apr;141(4):1504-1507.e3. doi: 10.1016/j.jaci.2017.11.031. Epub 2017 Dec 21.

13. Immunity and immunopathology in early human life. Kollmann TR, Marchant A. Semin Immunopathol. 2017 Nov;39(6):575-576. doi: 10.1007/s00281-017-0657-6. Epub 2017 Nov 23. No abstract available.

14. Modes of Infant Feeding and the Risk of Childhood Asthma: A Prospective Birth Cohort Study. Klopp A, Vehling L, Becker AB, Subbarao P, Mandhane PJ, Turvey SE, Lefebvre DL, Sears MR; CHILD Study Investigators, Azad MB. J Pediatr. 2017 Nov;190:192-199.e2. doi: 10.1016/j.jpeds.2017.07.012.

15. Newborn susceptibility to infection vs. disease depends on complex in vivo interactions of host and pathogen. Brook B, Harbeson D, Ben-Othman R, Viemann D, Kollmann TR. Semin Immunopathol. 2017 Nov;39(6):615-625. doi: 10.1007/s00281-017-0651-z. Epub 2017 Nov 2. Review.